Friedrich Bettina, Vindrola-Padros Cecilia, Lucassen Anneke M, Patch Chris, Clarke Angus, Lakhanpaul Monica, Lewis Celine
Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Department of Targeted Intervention and Rapid Research Evaluation and Appraisal Lab (RREAL), University College London, London, United Kingdom.
Front Genet. 2024 Jan 4;14:1282034. doi: 10.3389/fgene.2023.1282034. eCollection 2023.
The Genomic Medicine Service (GMS) was launched in 2018 in England to create a step-change in the use of genomics in the NHS, including offering whole genome sequencing (WGS) as part of routine care. In this qualitative study on pediatric rare disease diagnosis, we used an implementation science framework to identify enablers and barriers which have influenced rollout. Semi-structured interviews were conducted with seven participants tasked with designing the GMS and 14 tasked with leading the implementation across the seven Genomic Medicine Service Alliances (GMSAs) and/or Genomic Laboratory Hubs (GLHs) between October 2021 and February 2022. Overall, those involved in delivering the service strongly support its aims and ambitions. Challenges include: 1) concerns around the lack of trained and available workforce (clinicians and scientists) to seek consent from patients, interpret findings and communicate results; 2) the lack of a digital, coordinated infrastructure in place to support and standardize delivery with knock-on effects including onerous administrative aspects required to consent patients and order WGS tests; 3) that the "mainstreaming agenda", whilst considered important, encountered reluctance to become engaged from those who did not see it as a priority or viewed it as being politically rather than clinically driven; 4) the timelines and targets set for the GMS were perceived by some as too ambitious. Interviewees discussed local adaptations and strategies employed to address the various challenges they had encountered, including 1) capacity-building, 2) employing genomic associates and other support staff to support the consent and test ordering process, 3) having "genomic champions" embedded in mainstream services to impart knowledge and best practice, 4) enhancing collaboration between genetic and mainstream specialties, 5) building evaluation into the service and 6) co-creating services with patients and the public. Our findings highlight the challenges of implementing system-wide change within a complex healthcare system. Local as well as national solutions can undoubtedly address many of these barriers over time.
基因组医学服务(GMS)于2018年在英国启动,旨在使国民健康服务体系(NHS)中基因组学的应用实现跨越式发展,包括将全基因组测序(WGS)作为常规护理的一部分。在这项关于儿科罕见病诊断的定性研究中,我们运用实施科学框架来确定影响推广的促进因素和障碍。2021年10月至2022年2月期间,我们对7名负责设计GMS的参与者以及14名负责在7个基因组医学服务联盟(GMSA)和/或基因组实验室中心(GLH)领导实施工作的参与者进行了半结构化访谈。总体而言,参与提供该服务的人员强烈支持其目标和抱负。挑战包括:1)担心缺乏经过培训且可随时调用的劳动力(临床医生和科学家)来获取患者同意、解读结果并传达结果;2)缺乏数字化的协调基础设施来支持和规范服务提供,产生了连锁反应,包括获取患者同意和订购WGS检测所需的繁重行政工作;3)“主流化议程”虽被认为很重要,但那些不认为这是优先事项或认为其是政治而非临床驱动的人不愿参与;4)一些人认为为GMS设定的时间表和目标过于雄心勃勃。受访者讨论了为应对所遇到的各种挑战而采用的局部调整和策略,包括1)能力建设;2)聘用基因组学助理和其他支持人员来支持同意和检测订购流程;3)在主流服务中配备“基因组倡导者”以传授知识和最佳实践;4)加强遗传学和主流专科之间的合作;5)将评估纳入服务;6)与患者及公众共同创建服务。我们的研究结果凸显了在复杂的医疗系统中实施全系统变革所面临的挑战。随着时间的推移,地方和国家层面的解决方案无疑可以解决其中许多障碍。